<DOC>
	<DOC>NCT00502164</DOC>
	<brief_summary>A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.</brief_summary>
	<brief_title>Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Men, 18yrs and older Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic) Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma Prior radiotherapy to bone metastases within 4 weeks prior to screening any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
</DOC>